Viome Life Sciences aims to make illness optional by predicting and preventing chronic diseases through a deeper understanding of an individual’s biology at a molecular level. They focus on prevention, diagnostics, and therapeutics using direct-to-consumer services and advanced technology.

Naveen Jain

Viome Life Sciences

Viome Life Sciences was founded in 2016 with a mission to make illness optional by predicting and preventing chronic diseases, cancers, and aging through a deeper understanding of an individual's biology at a molecular level.

Viome's Consumer Services (VIOME) provides the industry's only direct-to-consumer healthcare test that analyzes microbial and human gene expressions (mRNA), with technology exclusively licensed from Los Alamos National Lab, in order to provide individuals with health insights and the nutrition they need.

Our Health Sciences division focuses on key initiatives including prediction, early diagnostics, prognostics, and precision therapeutics to help people live a disease free life. With our state of the art artificial intelligence platform, we are able to analyze data from the world's largest and richest gene expression database in order to identify the root causes of chronic diseases, cancers, and aging and the mechanisms of action to be able to prevent and reverse them. 

Prediction: Using advanced AI methods to discover host/microbial biomarkers that predict the risk of developing severe chronic conditions, including cancers.

Early Diagnostics: Using host/microbial biomarkers to diagnose severe chronic conditions including cancers at the earliest possible stage. Early diagnosis will enable earlier treatment which often is associated with higher efficacy.

Prognostics: Leveraging host/microbial biomarkers to develop companion diagnostics to predict drug effectiveness and further improve responsiveness of patients by proposing AI-guided modulation of the microbiome.

Therapeutics: By targeting the root cause of specific chronic diseases with prophylactics or therapeutics such as drugs, monoclonal antibodies, vaccines, phages, or other appropriate modalities.

Today, we are very excited to announce the launch of our groundbreaking Oral Health Pro + CancerDetect solution, our first step in creating an ecosystem of care where each individual receives the highest level of personalized healthcare and professionals have the tools and insights they need to make it possible. Dental practices have already been onboarded and will be the first to deliver this cutting-edge solution to their patients! 

Now, the opportunity is open to all dental professionals who can visit https://www.viomepro.com/.

Our technology empowers dentists to customize treatments for individual patients, transforming them from healthcare providers to trusted allies in their patients' health journeys. 

For Oral Healthcare Professionals & Practices: Our Oral Health Pro + CancerDetect solution offers an intuitive, dual-interface system via our professional portal and for Patients through their Viome account. With this, ordering tests and retrieving patient information becomes a breeze for both you and your patients. Our solution integrates seamlessly into their workflows, offering an array of benefits - from free educational resources to boosting patient retention and loyalty - all while maintaining optimal care without infringing upon their valuable chair time.

For Patients: Patients receive a home-delivered kit from Viome, allowing them to send their saliva samples with ease. The detailed Oral Health Pro report provides a comprehensive view of their oral health, enabling dentists to tailor highly personalized treatment plans.


Learn more at http://www.viomepro.com 
Or email us at OralCarePro@viome.com

#ViomeLifeSciences #Viome #OralHealthPro #CancerDetect #oralhealth #oralcancer #throatcancer #ViomePRO #healthcare #technology #health

“Stop dreaming small!”

Amazing conversation!  

Thank you Naveen Jain & Jay Shetty

At Viome, we analyze the biochemical activities within your gut microbiome with metatranscriptomics (RNA analysis) and AI algorithms, and create tailored nutritional plans to fit the unique needs of each individual. When we studied the difference between people who took advantage of our precision supplements and people who didn’t, we found that 77.3% of those who did improved their depression symptoms compared with 20.8% of those who didn’t. This shows that precision nutrition can be as much of a factor in your mental health as your physical health. Our latest pre-print on this study is just out 

https://lnkd.in/eEFh77HC

Metric
Company Name	Viome Life Sciences
Symbol
MSH ID	COM:VIOMELIFESCIENCES
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Healthcare & Health Services
Country	US
Stage
Employee Count	25
Website	viomelifesciences.com
LinkedIn	viomelifesciences
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:VIOMELIFESCIENCES

Viome Life Sciences

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue